Loading...
•
Sep 30, 2020
McKesson Q2 2021 Earnings Report
Reported an increase in revenue and adjusted earnings per share, driven by growth in the U.S. Pharmaceutical segment and Medical-Surgical Solutions segment.
Key Takeaways
McKesson reported a 6% increase in total revenues, reaching $60.8 billion. Earnings per diluted share increased to $3.54, and adjusted earnings per diluted share rose by 33% to $4.80. The company also completed a joint venture of its German wholesale business with Walgreens Boots Alliance.
Total revenues increased by 6% year-over-year to $60.8 billion.
Earnings per diluted share increased by $7.53 to $3.54.
Adjusted Earnings per diluted share increased by 33% to $4.80.
Fiscal 2021 Adjusted Earnings per diluted share guidance range increased to $16.00 to $16.50.
McKesson
McKesson
McKesson Revenue by Segment
Revenue by Segment
U.S. Pharmaceutical Revenue
CapyFin.comPrescription Technology Solutions Revenue
CapyFin.comMedical-Surgical Solutions Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
McKesson raised fiscal 2021 Adjusted Earnings per diluted share guidance to $16.00 to $16.50 from the previous range of $14.70 to $15.50, reflecting strong execution and earlier improvement in volumes relative to expectations through the first half of fiscal 2021.
Positive Outlook
- Strong execution
- Earlier improvement in volumes
- Adjusted Earnings per diluted share related to the kitting and storage of ancillary supplies for future COVID-19 vaccines: $0.15 to $0.20
Challenges Ahead
- Full recovery of pharmaceutical prescription volumes and patient visits is not likely to occur this fiscal year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income